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Key points 
1.  “Pathogenic” or “likely pathogenic” classified variants in known genes were 
discovered in 46% of index cases with an inherited thrombocytopenia of unknown 
aetiology. 
2. Whole exome sequencing combined with platelet phenotyping is a valuable 
research tool for discovering potentially pathogenic variants in known and novel 
genes for further research. 
 
  
Abstract 
Inherited thrombocytopenias are a heterogeneous group of disorders characterised 
by abnormally low platelet counts which can be associated with abnormal bleeding. 
Next generation sequencing has previously been employed in these disorders for the 
confirmation of suspected genetic abnormalities, and more recently in the discovery 
of novel disease causing genes. However its full potential has not previously been 
utilised. Over the past 6 years we have sequenced the exomes from 55 patients, 
including 37 index cases and 18 additional family members, all of whom were 
recruited to the UK Genotyping and Phenotyping of Platelets study.  All patients had 
inherited or sustained thrombocytopenia of unknown aetiology with platelet counts 
varying from 11-186x109/L. Of the 51 patients phenotypically tested, 37 (73%), had 
an additional secondary qualitative platelet defect. Using whole exome sequencing 
analysis we have identified “pathogenic” or “likely pathogenic” variants in 46% 
(17/37) of our index patients with thrombocytopenia.  In addition, we report variants 
of uncertain significance in 12 index cases which include novel candidate genetic 
variants in previously unreported genes in four index cases. These results 
demonstrate that whole exome sequencing is an efficient method for elucidating 
potential pathogenic genetic variants in inherited thrombocytopenia. Whole exome 
sequencing also has the added benefit of discovering potentially pathogenic genetic 
variants for further study in novel genes not previously implicated in inherited 
thrombocytopenia. 
 
 
 
 Introduction 
Inherited thrombocytopenias (IT) are a heterogeneous group of disorders 
characterised by platelet counts of less than 150x109/L in whole blood. Platelet 
counts are considered normal when maintained at levels between 150-450x109/L. 
This is achieved by homeostatic processes controlling platelet production 
(thrombopoiesis), platelet senescence and platelet consumption/destruction. 
Pathogenic mutations can result in a disruption of these balanced processes causing 
inherited thrombocytopenia. However, the clinical manifestation of bleeding is often 
dependent on both a decreased platelet count and a qualitative or acquired platelet 
defect. Clinical complications can vary dramatically from severe and potentially life 
threatening bleeding to being asymptomatic.  This variation is noted amongst 
individuals shown to have the same underlying genetic causes of disease, 
suggesting that bleeding risk and phenotype is a complex trait (1). 
The average incidence of IT is estimated to be approximately 270 cases per 1 million 
live births (2). To date there are 27 individual IT disorders with known causative 
mutations registered within OMIM, although 33 disease causing genes have been 
described (3). 
Genetic studies have played a major role in the diagnosis and progressive 
understanding of IT. The genes implicated in the disease encode proteins that vary 
widely in function and include transcription factors (ETV6, FLI1, GATA1, GFI1B and 
RUNX1) and proteins involved in cytoskeleton rearrangement and organisation 
(ACTN1, FLNA, GP1BA, GP1BB, GP9, TUBB1 and WAS). However, some protein 
functions currently remain unknown (SLFN14 and GNE) (4-9). Although our 
knowledge of the causes of IT continues to grow, presently a genetic diagnosis is 
only reported in approximately 50% of individuals (10-12).  
Previously, genetic investigation into IT has focused on candidate gene sequencing 
and individual cases of whole exome sequencing (WES) when a causative gene is 
not obvious (9). With 50% of patients currently undiagnosed, a change in the way we 
approach genetic diagnosis is necessary. Here we present the first large scale WES 
only approach to patients with suspected IT. We demonstrate its application in 
determining possible genetic origins of IT including identification of variants in novel 
candidate causative genes. We combine this with an approach implemented by the 
Genotyping and Phenotyping of Platelets (GAPP) study, which combines WES 
analysis with extensive platelet phenotyping to create a complete method of 
diagnosis and gene discovery in this subset of patients. 
Methods 
Study approval 
The UK-GAPP study was approved by the National Research Ethics Service 
Committee of West Midlands–Edgbaston (REC reference: 06/MRE07/36) and 
participants gave written informed consent in accordance with the Declaration of 
Helsinki. This study was registered at www.isrctn.org as #ISRCTN 77951167. The 
GAPP study is included in the National Institute of Health Research Non-Malignant 
Haematology study portfolio (ID9858). 
Platelet counts, morphology and white blood cell counts 
Patient samples were compared to the range of healthy volunteers for the specific 
method of morphology used. Platelet counts for light transmission aggregometry 
(LTA) and flow cytometry analysis as well as mean platelet volume (MPV) in platelet 
rich plasma (PRP) were originally measured using the Beckman coulter counter 
(n=44). Subsequently, platelet counts, morphology and white blood cell counts in 
whole blood were measured using the Sysmex XN-1000 (n=11). The PLT-F channel 
was used to determine platelet counts in whole blood and the immature platelet 
fraction (IPF). MPV was determined from the impedance PLT-I channel.  White blood 
cell counts were determined using the Sysmex XN-DIFF channel.  All samples were 
tested against a normal range which was established by measuring the counts for 40 
healthy individuals using the Sysmex XN-1000. 
Platelet preparation and platelet function testing 
Platelet function was assessed by light transmission aggregometry, including 
lumiaggregometry, for samples having platelet counts in PRP of >1x108/mL (n=13). 
An in-house flow-cytometry assay was developed to assess platelet function in 
patients having platelet counts in PRP <1x108/mL (n=22). Platelets from individuals 
with borderline platelet counts in PRP between 1.0 and 1.5x108/mL were assessed 
using both assays (n=16). 
Aggregometry was performed as previously described (13, 14). For flow cytometry, 
resting surface levels of CD42b, CD41 and GPVI were assessed. PRP was then 
stimulated with ADP (3 and 30 μM), CRP (0.3 and 3μg/ml) and PAR-1 peptide (10 
and 100 μM). Membrane expression of P-selectin (FITC-conjugated mouse anti-
human CD62P antibody, BD Pharmingen), a marker of platelet alpha granule 
release, as well as fluorescent fibrinogen binding (marker of integrin activation) was 
assessed by flow cytometry on an Accuri C6 flow cytometer. Incubation took place at 
37ºC for 2 min and was terminated by adding a fivefold excess of ice cold PBS. 
Whole exome sequencing 
WES and bioinformatics analysis was performed as described previously (8, 15, 16) 
(Figure 1).  
Pathogenicity of variants was determined and called using the consensus guidelines 
as set out by the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology (ACMG guidelines) (17). Segregation was 
determined by Sanger sequencing of candidate variants in both affected and 
unaffected family members, when available, and classification was adapted 
appropriately for the specific study and small sample size. 
Sanger sequencing 
To verify candidate mutations and examine their segregation among family members 
Sanger sequencing was performed using standard methods on an ABI 3730 
automated sequencer as described previously (8). 
Results 
Patient recruitment 
To date, 55 patients with a suspected IT or sustained reduced platelet counts have 
been enrolled from 25 UK Haemophilia Care Centres and investigated as part of the 
GAPP study. Before enrolment in the study, all patients underwent clinical and 
genetic work-up to exclude known platelet disorders (including Bernard-Soulier 
Syndrome and MYH9-related disorders, analysed initially by blood film), idiopathic 
thrombocytopenic purpura (ITP) and other non-platelet disorders including von 
Willebrand disease and inherited coagulation factor deficiencies. Patient bleeding 
phenotypes are displayed in Table 1. WES was performed on genomic DNA from all 
patients, including 37 index cases, all of whom met the study’s entry criteria. All 
patients, excluding F35.I and F35.II, were of white British or mixed British ethnicity. 
All results following platelet function testing and WES were reported back to the 
referring haematological consultants to aid in genetic counselling and disease 
management. 
Platelet counts, morphology and function testing 
Patients were recruited with a platelet count in whole blood, at the time of enrolment, 
of less than 150x109/L. Patients having platelet counts in the range of 150-200x109/L 
remained enrolled in the study if they showed a similar phenotype to related affected 
family members and a platelet count below 150x109/L had been observed prior to 
enrolment (patients F4.II, F11.III, F13.I and F30.II). Platelet counts, MPVs and IPFs 
are displayed in Table 1. Of the 55 recruited patients, 12 were deemed to have a 
macrothrombocytopenia and three a microthrombocytopenia (Table 1). White cell 
counts were within the normal range (normal range to 2SD 3.78 - 10.11x109/L, n=40) 
across all patients (n=11) analysed. 
Platelet function studies revealed the presence of a secondary qualitative defect in 
addition to the reduction in platelet count in 37/51 (73%) of the 55 patients whose 
DNA underwent WES and who were also available for platelet function testing (PFT) 
(Table 1). Of the 37 patients with a secondary qualitative defect, 89% (33/37) 
displayed defects in both alpha and dense granule secretion. Five of these patients 
with an observed granule secretion defect were also suspected to have an additional 
Gi defect due to a reduction in response to all concentrations of ADP. The remaining 
four patients without an observable granule secretion defect showed abnormalities in 
alternative pathways (Integrin activation, cyclooxygenase pathway and GPVI surface 
levels) in addition to the reduction in platelet count (Table 1). 
Whole exome sequencing 
WES was performed on genomic DNA from all 55 patients, comprising of 37 index 
cases, following PFT. Average fold coverage of 111 was observed across all DNA 
samples analysed by WES with an average of 91% of target sequences having >20x 
coverage. Areas of poor coverage were analysed manually when occurring in 
previously IT associated genes. 
WES revealed between 24,000 and 25,000 variants (SNVs, small scale 
insertions/deletions, and splice site variations) in the DNA from each patient, with an 
average of 197 novel variants per exome. On average, per individual, 2401 variants 
with a MAF of <0.01 were observed excluding synonymous variants. Over 99% 
sensitivity and an approximate 3% false discovery rate was found by evaluating the 
specificity of the pipeline in calling small variations. Percentage of the gene with 
≤20x coverage for panel of 358 platelet-related genes is included within 
Supplementary Table 1.  
CNVs were detected using ExomeDepth (18) and analysis revealed an average of 
137 CNVs per exome (n=32). No CNVs were deemed potential candidates either 
due to a high allele frequency or a lack of expression or functional role of the gene 
within the megakaryocyte/platelet lineage.   
Variants in known thrombocytopenia causing genes 
WES and downstream analysis identified variants in 25 index cases (68%) within the 
33 known IT causing genes. All variants exceeded 30x sequence coverage at the 
point of variation and have been confirmed by Sanger sequencing. Variants were 
selected from positive hits to genes within the panel of 358 IT associated genes 
(Supplementary Table 1). On average, 37 variants per individual (range 11-52) were 
noted in genes from the panel of 358 IT associated genes, of which on average four 
(range 0-7) variants were significant per exome analysed.  
In total 28 variants were noted in 14 genes previously known to cause IT (Table 2). 
Twenty-one index cases possessed a single variant in a gene previously known to 
cause IT. Four index cases possessed two variants in genes previously known to 
cause IT. One variant, RUNX1; c.270+1G>T, was noted in two index cases (F13.I 
and F14.I). Candidate variations were present within; ACTN1, the 5’-UTR of 
ANKRD26, CYCS, FLI1, GFI1B, ITGB3, GP1BA (heterozygous), MYH9, NBEAL2, 
RUNX1, SLFN14, STIM1, TPM4 and TUBB1. All but six variants were novel and not 
present within the variant databases previously mentioned. Three variants, 
ANKRD26; c.-126T>G in F2.I, MYH9; c.3493C>T (rs80338829) in F9.I and RUNX1; 
c.530G>A in F19.I and F19.II have been previously associated with IT (1, 19, 20). 
The remaining three variants that have been previously observed occurred at 
frequencies in available databases < 0.005 (0.05%). One of the databases 
scrutinised was that of the ExAC consortium (http://exac.broadinstitute.org) which 
may include data from individuals with low platelet counts who were either 
undiagnosed or recruited through an unrelated study (Table 2). Seven variants have 
previously been published as part of two separate publications from the UK-GAPP 
study group (8, 15). 
Classification of the 28 variants occurring within the known IT-related genes, 
following the interpretation guidelines as set out by Richards et al. (17), revealed  
four variants to be “pathogenic”, 13 to be “likely pathogenic” and 11 to be of 
“uncertain significance”. Variants classified as “pathogenic” were either already 
known to be a genetic cause of IT; ANKRD26; c.-126T>G in F2.I and MYH9; 
p.Arg1165Cys in F9.I, or were predicted loss of function variants in genes where a 
loss of function is known to cause disease; FLI1; p.Asn331Thr fs*4, in F4.I and F4.II 
and RUNX1; pTrp79* in P12.I. 
On average, less than one novel variant was expected to be observed in the known 
IT causing genes in which variants were observed. The number of variants occurring 
also exceeds the expected number when extending the analysis to cover variants 
with a MAF of <0.01. 
Of the 37 index patients, four presented with two candidate variations in known 
disease linked genes, which in one case were present in the same gene. These 
were as follows: F6.I (GFI1B; c.676+1G>A and STIM1; p.Ala610Thr), F10.I 
(NBEAL2; (p.Leu459Arg fs*13 and p.Asn2298Ser), F12.I (RUNX1; p.Trp79* and 
ITGB3 p.Arg117Trp) and F23.I (TPM4; p.Ala183Val and TUBB1; p.Phe242Leu). 
Of the 25 index cases having variants in known disease causing genes, nine were 
observed to have variants within the RUNT1-related transcription factor gene; 
RUNX1. One variant, RUNX1; p.Arg177Gln, observed in F19.I and F19.II has been 
previously reported as causative germline mutation of familial platelet disorder in two 
individuals from the same pedigree (20). The variations consisted of five missense 
variants, two splice-site variants and one nonsense variant. One splice-site variation, 
c.270+1G>T, was present within three affected individuals from two separate 
families (F13 and F14). All variants, with the exception of a missense substitution 
(p.D6N), lie within the genetic region encoding the RUNT homology domain (RHD) 
which mediates DNA binding and heterodimerization with CBFβ (Figure 2) (21). 
Platelets from the majority of these patients (10/13) demonstrated a reduction in ATP 
secretion and, in keeping with previous reports, several of these patients displayed 
additional clinical features. Variations in RUNX1 are associated with a propensity to 
myelodysplastic syndrome and acute myeloid leukaemia (AML). To date, 
haematological malignancies have not been reported in any patients; however, the 
brother of F16.1 did have a history of AML but was unavailable for testing. 
Potentially damaging variants in novel candidate genes 
After scrutinising individuals for variants within the panel of 358 platelet associated 
genes (Supplementary table 1), individuals without a variant in a previously IT 
associated gene were analysed for variants in novel genes. WES analysis revealed 
potentially damaging candidate variants occurring within three families with currently 
unknown genetic aetiology (Table 3). All candidate variants are novel (excluding a 
previously annotated variant in MKL1; p.Val575Met, which occurs at a frequency of 
0.007718 within the ExAC consortium), segregate with the disease status and have 
been confirmed by Sanger sequencing.  
Variants within ANKRD18A, GNE and FRMPD1 in two related individuals from 
consanguineous relationships 
WES analysis of two related patients (F35.I and F35.II) of South Asian ethnicity was 
approached differently to other patients in this study. Both patients displayed a 
similarly severe clinical phenotype with a significant reduction in circulating platelets 
(15x109/L). PFT revealed a reduction in P-selectin (CD62P) expression upon 
stimulation and variable fluorescent fibrinogen binding which was consistent across 
both affected individuals. The patients were cousins born from consanguineous 
relationships within a single consanguineous kindred so analysis was focused on 
identification of a shared homozygous variant due to the recessive segregation of 
disease. Three variants occurring within ANKRD18A; p.Glu799del, GNE; 
p.Gly447Arg and FRMPD1; p.Ala509Val were present within both affected 
individuals and within a tightly linked region of homozygosity on chromosome 9p. 
The variations within ANKRD18A and GNE were novel within the databases 
previously mentioned whereas the variant in FRMPD1 has been observed at a 
frequency of 0.0003708 including 39 times within the South Asian population 
(rs571037699). There is no ClinVar entry for this variant and all three variants are 
classified as variants of “uncertain significance”.  
One missense variant in the recently proposed IT linked gene; MKL1 
One individual was shown to harbour a rare frequency (<0.01) missense variant 
within the Megakaryoblastic Leukaemia (translocation) 1 gene; MKL1.  The variant 
was the only variant occurring within a gene of haemostatic relevance within 109 
significant novel variants. The variant; MKL1; c.1723G>A, p.Val575Met present in 
patient F37.I has been noted previously at a frequency of 0.0007718 (allele count of 
6/7774 in the ExAC consortium). The patient has a mild reduction in platelet count 
(130x109/L) with no secondary qualitative defects in platelet function observed. The 
variant is classified as of “unknown significance”. 
Novel missense candidate variants in PADI2 and TTF2  
A large kindred with three affected individuals and four unaffected related individuals 
were recruited to the study. A mild thrombocytopenia was observed within the family 
with platelet counts ranging from 80-186x109/L in the three affected individuals. All 
three affected individuals presented with a normal platelet size (7.9-8.6fL) and a mild 
reduction in secretion was observed in F30.I and F30.III which was not shared with 
F30.II. All affected individuals shared a similar bleeding phenotype, suffering from 
spontaneous epistaxis, excessive bruising and prolonged bleeding from minor 
wounds. WES analysis revealed 14 novel or rare frequency (<0.01) variants shared 
between the three affected individuals. Sanger sequencing of all 14 variants in four 
unaffected related individuals narrowed down candidates to only two missense 
variants; PADI2 (p.Lys499Arg) and TTF2 (p.His1089Asp). Both variants segregate 
with disease, not being present in the unaffected individuals. Both variants have 
been observed at a low frequency previously (<0.01) within the EXaC database 
(Table 3) and are currently classified as “uncertain significance”. 
  
Discussion 
Here we present the first large scale application of WES analysis to patients with 
inherited bleeding diatheses presenting with thrombocytopenia of unknown 
aetiology.  
Platelet counts and phenotypic presentation vary among our patients considerably 
which is consistent with the variability observed in the spectrum of IT. However, the 
majority of patients (73%) were noted to have a secondary qualitative defect in 
platelet function which may explain the disproportionate bleeding when compared to 
the patient’s platelet counts. A lack of consistency was noted in families 13 and 30 
where affected individuals are observed both with and without defects in platelet 
function. Clinical complications are shared among the affected family members so 
this most likely represents limitations in the sensitivity of platelet function testing or 
intra-familial variability.  
Overall, when considering pathogenicity WES analysis revealed 46% of index cases 
(17/37) to have a positive prediction of pathogenicity (classified “pathogenic” or 
“likely pathogenic” in a gene consistent with the patients phenotype and zygosity 
consistent with expected inheritance). Twenty-two percent of the index cases (8/37) 
were of uncertain/possible pathogenicity (results classified of “uncertain significance” 
in known IT causing genes). The remaining 32% of index cases (12/37) had a 
negative prediction of pathogenicity (no convincing variants identified in known 
causing genes). WES is not without its limitations and like with any genetic analysis 
all variants must be functionally confirmed as deleterious to the coded protein. 
However, our positive variant discovery rate is comparable to or exceeds previous 
large scale WES clinical multicentre studies of Mendelian disorders (22, 23).  
Focusing our genetic analysis on patients with unknown aetiology of disease with 
minor prior genetic testing has produced a spectrum of variants different from 
previous large scale targeted genetic studies of IT. Patients were recruited to the 
study with clinically diagnosed bleeding disorders of unknown aetiology. One caveat 
of this approach results in possible exclusion of individuals with known BSS and 
MYH9-related disorders as these two forms of IT are routinely tested for in many 
haematological centres within the UK. However, 3 index cases have been noted with 
variants in either GP1BA or MYH9 in our analysis representing cases with atypical 
presentation of BSS or MYH9-related disorder and therefore potentially falsely-
negatively reported cases. The individuals with variants within GP1BA and MYH9 
showed a slight increase in MPV; however this was not at the magnitude of giant 
platelets normally attributed to this group of disorders and only patient F9.I showed 
any secondary syndromic symptoms with the individual suffering from congenital 
cataracts. 
One attribute of excluding patients with known variants in GP1BA, GP1BB, MYH9 
and potentially GP9 is the discovery of a relatively large percentage of individuals 
analysed (24% of index cases) with variants in RUNX1 as a primary likely cause of 
disease. With the exception of one predicted loss of function variant, the variants 
present within RUNX1 are currently classified as either “likely pathogenic” or of 
“uncertain significance” and need functional confirmation to be disease causing. 
However, the presence of these variants in a large number of individuals with an 
often shared secondary functional defect in secretion does suggest the prevalence of 
RUNX1 variants may be higher than previously thought. This raises the question 
whether it should be considered as clinically significant as BSS and MYH9-related 
disorders and be primarily screened for genetically upon initial diagnosis with IT.  
An advantage of using WES is the lack of limitations allowing the possibility of finding 
candidate variations in novel genes in cases that did not possess variants in known 
IT genes. To determine whether these variants are pathogenic relies on functional 
confirmation of the deleterious effect of the variant. However, WES analysis, 
especially with combined segregation analysis by Sanger sequencing in extensive 
kindreds, can provide indications as to which may be of scientific and clinical 
relevance. This strategy has recently been utilised in the discovery of novel 
candidate variations in SLFN14 initially as part of the GAPP study (15, 24). 
Family 35 is an interesting case of two affected related individuals born from 
consanguineous relationships. The molecular function of ANKRD18A is currently 
unknown and FRMPD1 functions to regulate the subcellular localisation of activator 
of G-protein signalling 3 (AGS3) (25). Both genes show weak expression in cells of 
the haematopoietic lineage, however, GNE; an enzyme in the sialic acid biosynthetic 
pathway, is expressed within all cells of the haematopoietic lineage. There are 
currently 88 registered mutations in GNE within the Human Genome Mutation 
Database (www.hgmd.cf.ac.uk). Mutations are known to be the genetic cause of 
sialuria (OMIM269921) and Hereditary Inclusion Body Myopathy (HIBM; 
OMIM600737) (26, 27). Recently, two separate groups have reported patients with 
compound heterozygous variations in GNE, causing GNE related myopathy with 
congenital thrombocytopenia (28, 29). Platelet counts within the four reported 
affected individuals were below 45x109/L; however no MPV measurements were 
recorded. None of the patients displayed signs of myopathy until mid-
adolescence/early adulthood; F35.I and F35.II are currently aged 10 and 6 
respectively. Without functional characterisation of the effects of each variation, we 
cannot definitively conclude the genetic aetiology of these two individuals’ severe 
thrombocytopenia. However, WES analysis has allowed us to focus our efforts on 
three potentially pathogenic variants in novel genes. 
MKL1 was initially included in our panel of 358 genes for post WES analysis due to 
its role in megakaryocyte maturation elucidated via its binding partner Serum 
response factor (SRF) (30-32). Recently, the first case of a homozygous mutation in 
MKL1 in a patient with a severe immunodeficiency and no haematological 
malignancies was reported (33). One interesting phenotypic presentation within the 
affected individual was an intermittent mild thrombocytopenia with a reduced platelet 
count in whole blood of 50-150x109/L. Here we present one novel variant within 
MKL1, at a highly conserved genetic site.  The missense variant observed in F37.I 
represents the only variant to occur in a gene with previous haematological 
implications. One further variant in MKL1 was observed in addition to a “likely 
pathogenic” frameshift causing insertion within TUBB1 in patient F25.I. Due to the 
predicted loss of function of the frameshift causing TUBB1 variant it is unlikely that 
the variant with MKL1 is additive to patient F25.I’s phenotype. However, the 
presence of the variant of uncertain significance in patient F37.I is an interesting 
candidate to take forward for functional studies. 
WES and segregation determination using Sanger sequencing revealed candidate 
variants in PADI2 and TTF2 that segregate with disease in F30.I, .II and .III. 
Phenotypic presentation does vary between the patients but clinical presentation 
remains consistent which may reflect limitations in the sensitivity of platelet function 
testing. Neither gene has previously been implicated in haematological abnormalities 
with mutations in PADI2 causing schizophrenia, breast cancer and rheumatoid 
arthritis, and mutations in TTF2 associated with Thyroid dysgenesis (34-37). WES 
analysis has therefore provided us with the first steps in determining the impact of 
these two variants of uncertain significance and whether they have the propensity to 
be disease causing. 
In summary, we show WES can be applied to identify the underlying genetic cause 
in known IT causing genes for patients with thrombocytopenia and unclear 
aetiologies of disease. We show similar positive detection rates when compared to 
prior targeted studies and with the addition of complementary functional studies 
show an improved detection rate when compared to WES analysis of other 
developmental disorders. We also suggest the applicability of WES in providing 
preliminary insight into novel genes and their potential mechanism of action through 
candidate variations of unknown significance. This approach provides a foundation 
to enhance our current knowledge on megakaryopoiesis, platelet function and 
platelet senescence/death upon subsequent functional studies.
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Table legends 
Table 1 
Platelet and bleeding phenotypes of 55 patients recruited to the UK-GAPP study. Average 
platelet count = 85x109/L (normal range to 2SD 147-327x109/L, n=40). Average MPV = 10fL 
(mean normal range to 2SD 7.8-12.69fL, n=40). IPF was available for 11 patients and varied 
between 1.8-87% (normal range 1.3-10.8%, n=40). Patients with an observed macro and micro 
thrombocytopenia are denoted by a + and -, respectively, following their most recent analysed 
MPV. Secondary qualitative defects are abbreviated to the following; (Gi) - reduction in response 
upon ADP stimulation indicating a possible defect in the Gi pathway, (GPVI) – reduction in surface 
GPVI quantity. Bleeding diathesis of each individual is summarised under bleeding phenotype. 
Table 2 
Results of whole exome sequencing analysis of 55 patients with inherited 
thrombocytopenia showing variants in known thrombocytopenia causing genes. 68% of 
individuals have a predicted genetic aetiology in a previously IT associated gene. When a variant 
has been previously observed it is annotated in the prevalence column with the database it is 
observed in. The ACMG consensus guideline results are also displayed in the final column (17). 
Table 3 
Potentially damaging variants in novel candidate genes. When a variant has been previously 
observed it is annotated in the prevalence column with the database it is observed in. PhyloP 
scores vary between -14 and +6 and measure conservation at each individual base, sites 
predicted to be conserved are assigned a positive score, fast evolving sites are assigned a 
negative score. Mutationtaster uses a Beyes classifier to predict the effect of a mutation from a 
feed a classifiers. SIFT damaging prediction score= <0.05. Provean deleterious score = <-2.5. 
PolyPhen-2 predictions are appraised qualitatively as benign or damaging.  The ACMG consensus 
guidelines, including supporting evidence, are also shown. 
Table 1 
Family Patient Platelet count (x109/l) MPV (fL) IPF (%) Secondary defect Bleeding Phenotype 
1 I 73 9.6  Yes (Fibrinogen) Cutaneous bruising/bleeding, menorrhagia 
2 I 50 8.6  No Cutaneous bruising 
3 I 80 10.3  Yes (Cyclooxygenase) Cutaneous bruising, menorrhagia 
 II 50 12  Yes (Cyclooxygenase) Cutaneous bruising, epistaxis, purpura 
 III 98 10.5 3.2 N/A Cutaneous bruising, epistaxis, purpura 
4 I 142 11.8+  Yes (Secretion and Gi) Oral cavity bleeding, epistaxis, menorrhagia 
 II 157 11.4+  Yes (Secretion) Cutaneous bruising, oral cavity bleeding 
5 I 92 8.8  Yes (Secretion) Cutaneous bruising, epistaxis, bleeding into joints 
 II 100 8.6  Yes (Secretion) Cutaneous bruising, life threatening bleeding following surgery 
6 I 110   Yes (Secretion) Cutaneous bruising, excessive bleeding following surgery 
 II 100 8.9  Yes (Secretion) Cutaneous bruising, epistaxis 
7 I 50 10.4  Yes (Secretion) Cutaneous bruising, menorrhagia 
8 I 70 10.7+  No Cutaneous bruising, menorrhagia, post-partum haemorrhage 
 II 70 10.1  No Cutaneous bruising, epistaxis, haematuria, menorrhagia, post-partum haemorrhage 
9 I 35 11.4+  No Epistaxis, cutaneous bruising. 
10 I 55   N/A Cutaneous bruising, epistaxis 
11 I 62   Yes (Secretion) Cutaneous bruising 
 II N/A   Yes (Secretion) Cutaneous bruising, epistaxis 
 III 146   Yes (Secretion) Cutaneous bruising, epistaxis, menorrhagia 
12 I 100 8  Yes (Secretion) Excessive cutaneous bleeding 
13 I 163 9.1  No Cutaneous bruising, epistaxis, haematoma 
 II 45 11.9+  Yes (GPVI) Cutaneous bruising, epistaxis 
14 I 139 8  Yes (Secretion) Epistaxis, haematoma 
15 I 90 7.6-  Yes (Secretion) Cutaneous bruising, petechiae 
16 I 130 7.1-  Yes (Secretion and Gi) Cutaneous bruising, epistaxis, oral cavity bleeding 
 II 70 7.5-  Yes (Secretion and Gi) Cutaneous bruising, epistaxis, oral cavity bleeding 
17 I N/A N/A  N/A Excessive bruising/bleeding 
18 I 110 8.1  Yes (Secretion) Cutaneous bruising/bleeding, petechiae, haematoma 
19 I 100 9  No Cutaneous bruising/bleeding 
 II 100 9.2  No Cutaneous bruising/bleeding 
20 I 89 13+ 17.5 Yes (Secretion and Gi) Cutaneous bruising 
21 I 63 11.9 19.1 Yes (Secretion) Cutaneous bruising, epistaxis, haematoma 
 II 83 11.9 24.3 Yes (Secretion) Cutaneous bruising, epistaxis, haematoma 
22 I 74 11.2  Yes (Secretion and Gi) Cutaneous bruising/bleeding, haematuria 
 II 62 12.7+ 20.8 Yes (Secretion and Gi) Cutaneous bruising/bleeding, menorrhagia, post-partum haemorrhage, haematoma 
 III 109 11  Yes (Secretion) Cutaneous bruising, haematoma, menorrhagia 
23 I 119 11.1  Yes (Secretion) Cutaneous bruising/bleeding 
24 I 104 9.6  No Menorrhagia, post-partum haemorrhage 
 II 133 8.6  No Epistaxis 
25 I 11 13.4+  Yes (Secretion and Gi) Cutaneous bruising 
26 I 43 14+  No Cutaneous bruising, menorrhagia, oral cavity bleeding 
27 I 100 10.3  Yes (Secretion) Cutaneous bruising/bleeding, epistaxis, oral cavity bleeding 
28 I 25 8.5  Yes (Secretion) Cutaneous bruising 
29 I 15 9.4  Yes (Secretion) Haematomas 
30 I 137 7.9  Yes (Secretion) Cutaneous bruising, epistaxis, menorrhagia 
 II 186 8.6  No Cutaneous bruising, menorrhagia, haematuria 
 III 80 8.2  Yes (Secretion) Cutaneous bruising 
31 I 20 9.7  N/A Cutaneous bruising, epistaxis, oral cavity bleeding 
32 I 15 9.5 20.2 No Cutaneous bruising 
33 I 66 9.9 1.8 Yes (Secretion) Cutaneous bleeding 
34 I 93 14.4+ 20.5 Yes (Secretion) Cutaneous bleeding, epistaxis 
35 I 15 10.4 87 Yes (Secretion and 
other) Cutaneous bruising, epistaxis, haematomas 
 II 14 15+ 83 Yes (Secretion and 
other) Cutaneous bleeding 
36 I 104 13.3+ 17 No Menorrhagia 
37 I 130 9.7  No Cutaneous bruising, epistaxis, menorrhagia 
  
  
Table 2 
Family Patient Gene(s) Genomic variation Protein effect Variation type Prevalence Classification 
1 I ACTN1 c.2647G>C p.Gly883Arg Missense Novel Likely Pathogenic 
2 I ANKRD26 c.-126T>G  5'-UTR variation Known Pathogenic 
3 I CYCS c.155C>T p.Ala52Val Missense Novel 
Likely Pathogenic  II CYCS c.155C>T p.Ala52Val Missense Novel 
 III CYCS c.155C>T p.Ala52Val Missense Novel 
4 I FLI1 c.992_995del p.Asn331Thr fs*4 Frameshift deletion Novel Pathogenic 
 II FLI1 c.992_995del p.Asn331Thr fs*4 Frameshift deletion Novel 
5 I FLI1 c.1028A>G p.Tyr343Cys Missense Novel Likely Pathogenic 
 II FLI1 c.1028A>G p.Tyr343Cys Missense Novel 
6 I GFI1B c.814+1G>A  Splicing Novel Likely Pathogenic STIM1 c.1828G>A p.Ala610Thr Missense 0.00019 (1k) Uncertain significance 
 
II GFI1B c.814+1G>A  Splicing Novel Likely Pathogenic STIM1 c.1828G>A p.Ala610Thr Missense 0.00019 (1k) Uncertain significance 
7 I GP1BA c.1761A>C p.Gln587His Missense 0.00043 (EXaC) (rs570515282) Uncertain significance 
8 I GP1BA c.413G>T p.Gly138Val Missense Novel Likely Pathogenic 
 II GP1BA c.413G>T p.Gly138Val Missense Novel 
9 I MYH9 c.3493C>T p.Arg1165Cys Missense Known (rs80338829) Pathogenic 
10 I NBEAL2 c.1376delT p.Leu459Arg fs*13 Frameshift deletion Novel Likely Pathogenic NBEAL2 c.6893A>G p.Asn2298Ser Missense Novel Likely Pathogenic 
11 I RUNX1 c.16G>A p.Asp6Asn Missense Novel 
Likely Pathogenic  II RUNX1 c.16G>A p.Asp6Asn Missense Novel 
 III RUNX1 c.16G>A p.Asp6Asn Missense Novel 
12 I RUNX1 c.236G>A p.Trp79* Nonsense Novel Pathogenic ITGB3 c.349C>T p.Arg117Trp Missense Novel Uncertain significance 
13 I RUNX1 c.270+1G>T   Splicing Novel 
Likely Pathogenic  II RUNX1 c.270+1G>T   Splicing Novel 
14 I RUNX1 c.270+1G>T  Splicing Novel 
15 I RUNX1 c.322G>A p.Gly108Ser Missense Novel Uncertain significance 
16 I RUNX1 c.427+1G>T  Splicing Novel Likely Pathogenic 
 II RUNX1 c.427+1G>T  Splicing Novel 
17 I RUNX1 c.505A>G p.Thr169Ala Missense Novel Uncertain significance 
18 I RUNX1 c.512A>T p.Asp171Val Missense Novel Uncertain significance 
19 I RUNX1 c.530G>A p.Arg177Gln Missense Known Likely Pathogenic 
 II RUNX1 c.530G>A p.Arg177Gln Missense Known 
20 I SLFN14 c.652A>G p.Lys218Glu Missense Novel Uncertain significance 
21 I SLFN14 c.657A>T p.Lys219Asn Missense Novel Uncertain significance 
 II SLFN14 c.657A>T p.Lys219Asn Missense Novel 
22 I SLFN14 c.659T>A p.Val220Asp Missense Novel 
Likely Pathogenic  II SLFN14 c.659T>A p.Val220Asp Missense Novel 
 III SLFN14 c.659T>A p.Val220Asp Missense Novel 
23 I TPM4 c.548C>T p.Ala183Val Missense Novel Uncertain significance TUBB1 c.726C>G p.Phe242Leu Missense Novel Uncertain significance 
24 I TUBB1 c.721C>T p.Arg241Trp Missense 0.0001071 (ExAC)(rs368923302) Uncertain significance 
 II TUBB1 c.721C>T p.Arg241Trp Missense 0.0001071 (ExAC)(rs368923302) 
25 I TUBB1 c.1080_1081insG p.Leu361Ala fs*19 Frameshift insertion Novel Likely Pathogenic 
26 I Unknown      
27 I Unknown           
28 I Unknown      
29 I Unknown           
30 I Unknown      
 II Unknown      
 III Unknown      
31 I Unknown           
32 I Unknown      
33 I Unknown           
34 I Unknown      
35 I Unknown           
 II Unknown      
36 I Unknown           
37 I Unknown      
Table 3  
Family Gene Variant Protein effect Prevalence PhyloP PhastCons Mutation taster SIFT Provean PolyPhen-2 ACMG Classification 
30 PADI2 c.1496A>G p.Lys499Arg 0.000008681 1.647 1 Disease causing Tolerated Neutral Benign PM (segregation)  Uncertain Significance TTF2 c.3265C>G p.His1089Asp 1.65E-05 5.131 1 Disease causing Damaging Deleterious Damaging PM (segregation) , PP3  Uncertain Significance 
35 
ANKRD18A c.2395_2397delhom p.Glu799delhom Novel 0.772 0.965 Polymorphism NA Deleterious NA PM2, PP (segregation), PM6 Uncertain Significance 
GNE c.1339G>Ahom p.Gly447Arghom Novel 5.343 1 Disease causing Damaging Neutral Damaging PM2, PP (segregation), PM6 Uncertain Significance 
FRMPD1 c.1526C>Thom p.Ala509Valhom 0.0003708 -1.459 0 Polymorphism Tolerated Neutral Benign PP (segregation), PM6 Uncertain Significance 
37 MKL1 c.1723G>A p.Val575Met 0.0007718 3.358 1 Disease causing Damaging Neutral Damaging  Uncertain Significance 
Figure 1 
Bioinformatics pipeline analysis of whole exome sequencing data. Initial WES analysis 
focused upon comparison to a panel of 358 genes (supplementary table 1). After which screening 
of exomes variants focused upon novel variants. Variant classification was performed utilising the 
ACMG consensus guidelines. 
Figure 2 
Spatial amino acid locations of all thrombocytopenia causing variants present within RUNT 
transcription factor 1 (RUNX1) (RefSeq NP_001001890). Previously disease causing variants 
found within the HGMD (www.hgmd.cf.ac.uk) and ClinVar (www.ncbi.nlm.nih.gov/clinvar/) 
databases are denoted above. The eight variants found within RUNX1 in the GAPP cohort of 54 
patients who have undergone whole exome sequencing are denoted below and the effect on the 
protein or predicted splice-site shown. 


Supplementary Table 1
IT related panel genes utilised for WES bioinformatics analysis. Percentage of each gene covered ≤20x is also shown.
Gene Percentage	  covered	  20x
ABCA12 95,78903846
ABCB4 91,87596154
ABCC4 94,33057692
ABCG5 94,33923077
ABCG8 94,58923077
ACSL4 89,83423077
ACTN1 95,97653846
ACVRL1 86,78846154
ADAMTS13 82,55192308
ADCY3 94,18192308
ADCY6 96,89115385
ADCY7 93,01884615
ADORA2B 99,71942308
ADRA2A 88,06634615
ADRA2B 99,77769231
ADRBK1 96,19711538
AK3 55,78346154
AKT1 96,86942308
AKT2 95,20153846
ALOX12	  	  	   93,64807692
ANKRD12 93,75903846
ANKRD18A 33,42519231
ANKRD18B 33,72769231
ANKRD26 88,99711538
ANKRD33 99,03942308
AP3B1 94,50730769
AP3D1 91,79173077
AP3M1 96,0675
AP3S1 52,58692308
APC 98,35365385
ARHGAP1 92,67423077
ARHGAP17 90,04076923
ARHGAP32 97,34884615
ARHGAP6 90,92846154
ARHGDIA 99,87653846
ARHGDIB 94,91942308
ARHGEF12 94,94096154
ARHGEF3 92,61442308
ARRB1 96,75096154
ASPN 95,82096154
BAK1 84,71307692
BCL2L1 95,73134615
BCOR 95,31596154
BET1L 88,50326923
BLOC1S1 87,50596154
BLOC1S2 84,00711538
BLOC1S3 64,64711538
BLOC1S4 0
BLOC1S5 0
BLOC1S6 0
BMP4 99,61769231
BTBD9 88,92961538
BTK 90,95365385
C14orf133 93,49211538
C19orf55 95,45673077
C20orf42	   98,17076923
C6orf25 94,98673077
CD226 96,20423077
CD36 95,57326923
CHD3 87,89211538
CLEC1B 84,17692308
CLEC4F 96,99903846
CNO 68,97596154
CSK 91,53903846
CTTN 92,78730769
CYCS 76,61653846
DAAM1 91,85519231
DIAPH1 90,83076923
DIAPH2 88,93423077
DIAPH3 90,49826923
DNAH11 94,54923077
DNM1L 90,95442308
DNM2 90,57903846
DNM3 93,96403846
DTNBP1 97,78865385
EFNB1 94,40038462
EPHA4 96,95403846
EPHB1 92,37596154
ERG 96,33038462
ETS1 96,40730769
ETV6 95,02826923
EXOC1 93,74442308
F2R	   98,79557692
F2RL3	   94,01692308
FARP2	   95,73269231
FCER1G 83,29288462
FCGR2A 67,57211538
FERMT1 91,73211538
FERMT3 95,51115385
FGD3 94,28884615
FGR 98,005
FHOD1 96,28326923
FLI1 94,73076923
FLII 93,37019231
FLNA 97,00788462
FMNL1 81,43192308
FMNL3 92,46903846
FYN 95,37461538
GATA1 92,99692308
GDI2 85,11634615
GFI1 95,03865385
GFI1B 94,83923077
GNA12 91,09903846
GNA13 99,22730769
GNAI1 83,15596154
GNAI2 97,37134615
GNAQ 82,19326923
GNAZ 99,58403846
GNB2 95,55461538
GNB3 98,4325
GNG11 95,51576923
GNG12 99,955
GNG13 82,95346154
GNG5 57,10211538
GP1BA 98,47846154
GP1BB 48,24865385
GP5	   94,20826923
GP6 87,45961538
GP9 85,64980769
GRAP2 92,87307692
GRB2 96,925
GRK5 93,96980769
GRK6 93,00576923
GUCY1A3 99,19346154
GUCY1B3 94,70807692
HBB 100
HOOK3 90,58788462
HOXA11 98,39903846
HPS1 90,14211538
HPS4 97,02096154
HTR2A 98,28846154
INPP5D 96,43903846
ITGA2 94,87115385
ITGA2B 90,47326923
ITGA5 92,47230769
ITGB1 91,83923077
ITGB3 91,50692308
ITPR1 94,55153846
JAK2 91,67096154
JMJD1C 96,59538462
KIAA1109 96,005
KIAA2018 99,5275
LAIR1 92,38615385
LAT 96,34288462
LCP2	   90,20923077
LPAR1 98,79923077
LTBP1 93,08288462
LY6G6F 98,07923077
LYN 90,19884615
LYST 95,22557692
MAP2K2 94,87903846
MAP2K4 71,90673077
MAP3K9 93,925
MAPK1 96,88
MAPK13 98,06653846
MAPK14 98,94038462
MAPK8 96,26557692
MDS1 0
MECOM 97,42153846
MKL1 92,5525
MLK1 0
MLPH 83,94865385
MMP17 83,83634615
MNX1 64,92788462
MPL 95,89403846
MRPS34 96,49923077
MUC16 98,12096154
MUC2 92,51884615
MUTED 95,05711538
MYB 92,59384615
MYH10 95,62423077
MYH13 88,64865385
MYH9 96,80057692
MYL9 90,89884615
MYLK 95,07519231
MYLK2 93,62173077
MYO18B 89,13384615
MYO3A 93,55019231
MYO5A 94,82423077
MYO5B 87,30557692
NAPA 95,39730769
NAPG 92,46403846
NBEA 86,9125
NBEAL2 97,56807692
NFE2 99,05153846
NIPSNAP3A 90,91269231
NOTCH1 89,38865385
NOX1 88,43692308
NRG3 96,13076923
NSF 37,36192308
NXF1 94,20769231
ORAI1 92,00634615
P2RX1 96,11173077
P2RY1 99,26365385
P2RY12 100
P2RY13 100
PDE2A 90,25076923
PDE3A 90,60538462
PDE4D 93,30769231
PDE5A 95,16384615
PDPK1 36,81807692
PDZD3 95,2925
PDZK1 15,58576923
PEAR1 96,45153846
PECAM1 100
PGM3 94,78634615
PHOX2A 54,54903846
PIK3CA 90,36384615
PIK3CB 94,71692308
PIK3CD 87,63288462
PIK3CG 98,25461538
PIK3R1 95,99730769
PIK3R3 96,83307692
PIK3R5 96,96980769
PLA2G4A 96,91615385
PLA2G4C 93,49153846
PLCB2 97,0875
PLCB3 92,18576923
PLCG2 94,48692308
PLDN 75,15980769
PPP1CA 99,00038462
PPP1CB 97,86730769
PPP1CC 98,79423077
PPP1R12A 91,18615385
PPP1R12C 78,43576923
PPP1R14A 85,47346154
PPP1R2 45,66384615
PRKACA 96,39538462
PRKACB 92,21788462
PRKACG 100
PRKAR1A 77,49673077
PRKAR2A 94,83557692
PRKCA 92,09307692
PRKCB 94,39903846
PRKCD 96,76076923
PRKCQ 91,7475
PRKD1 98,66307692
PRKG1 91,3625
PRKG2 95,72442308
PTEN 83,83673077
PTGIR 92,86269231
PTGS1 99,03711538
PTK2 93,98653846
PTPN1 93,99519231
PTPN11	   55,94115385
PTPN12 95,05057692
PTPN18 91,53596154
PTPN2 70,88884615
PTPN6 94,96384615
PTPN7 88,78
PTPN9 92,46019231
PTPRA 97,68
PTPRC 91,14269231
PTPRJ 92,07307692
RAB27A 99,31019231
RAB27B 97,62057692
RAB38 99,27326923
RAB4A 90,98846154
RABGGTA 90,39365385
RAC1 56,83538462
RAF1 93,3425
RAI1 98,35096154
RAP1B 58,62884615
RAP1GAP 92,23673077
RAP1GAP2 94,07826923
RAP1GDS1 85,94403846
RASGRP2 90,82
RBM8A 85,60326923
RGS10 90,32192308
RGS18 94,02134615
RGS19 96,77903846
RGS20 91,42634615
RGS9 92,94538462
RHOA 95,28730769
RHOC 96,63519231
RHOF 92,28615385
ROCK1 86,35980769
ROCK2 94,94538462
RUNX1 89,41538462
SCAMP2 87,93230769
SCAMP5 85,06346154
SCFD1 94,55307692
SELP 94,06769231
SERPINE2 93,29230769
SH2B3 87,26384615
SIRPA 74,93711538
SLC35D3 90,26326923
SLC9A3R1 94,555
SLC9A3R2 75,83384615
SLFN14 95,47711538
SMAD1 97,22134615
SMAD6 79,03769231
SNAP23 89,95788462
SNAP25 89,25403846
SNAP29 99,19
SNAPIN 93,63538462
SNX1 88,6075
SRA1 94,33307692
SRC 88,58730769
SRF 91,81730769
STIM1 90,21519231
STOM 91,51615385
STX11 99,55711538
STX12 96,40942308
STX2 90,69057692
STX4 93,61519231
STX6 96,60596154
STX7 98,15153846
STXBP1 95,39442308
STXBP2 96,60769231
STXBP3 93,66923077
STXBP4 93,48961538
STXBP5L 95,54057692
STXBP6 88,68615385
SUZ12 70,34346154
SYK 97,63346154
SYTL3 91,77326923
SYTL4 93,77846154
TAL1 76,37923077
TAOK1 93,57307692
TBXA2R 82,61076923
TEC 91,73115385
TGFBR3 94,92346154
THPO 90,60980769
TLN1 97,19653846
TLR2 98,30980769
TMCC2 90,78711538
TPM1 96,63076923
TPM4 77,58057692
TRAF4 95,36480769
TREML1 98,26788462
TRPM7 94,52211538
TTC37 97,67211538
TUBA3C 76,80365385
TUBB1 99,98019231
UNC13A 94,45807692
UNC13B 97,44692308
VAMP2 99,25480769
VAMP3 98,30519231
VAMP7	   16,34615385
VAMP8 84,83596154
VAV1 91,29730769
VAV2 95,41961538
VAV3 94,33903846
VPS11 98,45057692
VPS16 94,97403846
VPS18 98,01461538
VPS33A 95,89807692
VPS33B 95,43365385
VPS39 94,17423077
VPS41 91,65442308
VPS4B 97,05673077
VPS52 92,45634615
VPS8 90,68557692
VWF 75,24192308
WAS 82,84884615
WDR66 92,87173077
ZFPMI 66,54634615
IT related panel genes utilised for WES bioinformatics analysis. Percentage of each gene covered ≤20x is also shown.
